CBMG:NSD-Cellular Biomedicine Group, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 18.39

Change

-0.31 (-1.66)%

Market Cap

USD 0.36B

Volume

0.04M

Average Target Price

USD 28.00 (+52.26%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Cellular Biomedicine Group, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer and stem cell therapies for degenerative diseases in Greater China. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for treating a range of cancer indications comprising technologies in chimeric antigen receptor modified T cells (CAR-T), T-cells with genetically modified, tumor antigen-specific T-cell receptors, and next generation neoantigen-reactive bio-markers based tumor infiltrating lymphocytes; and human adipose-derived mesenchymal progenitor cells for the treatment of joint diseases The company's CAR-T products include CD20 for use in anti-tumor activities; CD22, a surface maker highly expressed in B cell malignancies in hairy cell leukemia; and B-cell maturation antigen therapies for treating refractory multiple myeloma in patients. It also develops NKG2D CAR therapies for use in NK cell signaling; alpha fetoprotein TCR-T therapies for treating hepatocellular carcinoma; tumor infiltrating lymphocyte therapies for treating immunogenic cancers; and knee osteoarthritis therapies, including AlloJoin therapy, which is in a Phase II clinical trial, as well as Re-Join that has completed the Phase IIb clinical trial. In addition, it engages in biopharmaceutical businesses, including research and development, technical support, technical service, and technology transfer activities in biomedical technology field; manufacturing non-food, pharmaceutical polypeptides, and medical devices; and the wholesale of cosmetics, sanitary products, and biological agents. The company has a collaboration agreement with Novartis Pharma AG to manufacture and supply their CAR-T cell therapy Kymriah in China. Cellular Biomedicine Group, Inc. was incorporated in 2001 and is headquartered in New York, New York. Address: 1345 Avenue of Americas, New York, NY, United States, 10105

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-11-30 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

+1.04 (+0.46%)

USD58.95B 22.22 17.39
REGN Regeneron Pharmaceuticals, Inc

+1.98 (+0.39%)

USD54.85B 18.84 14.53
MRNA Moderna, Inc

+25.71 (+20.24%)

USD50.27B N/A N/A
SGEN Seagen Inc

+1.19 (+0.70%)

USD30.27B 63.87 62.62
ALXN Alexion Pharmaceuticals, Inc

-1.72 (-1.39%)

USD27.10B 28.74 26.92
BNTX BioNTech SE

+14.25 (+12.96%)

USD26.48B -99,999.99 N/A
RPRX Royalty Pharma plc

+1.00 (+2.40%)

USD26.01B 22.60 9.74
GMAB Genmab A/S

+1.48 (+3.99%)

USD24.32B 26.59 2.61
BGNE BeiGene, Ltd

-30.20 (-10.56%)

USD24.20B N/A N/A
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing CBMG

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 13.24% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 13.24% N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain 2.68% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 2.68% N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain -20.53% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -20.53% N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 9.12% N/A N/A 63% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 9.12% N/A N/A 60% D-
Risk Return Profile  
Volatility (Standard Deviation) 53.98% N/A N/A 21% F
Risk Adjusted Return 16.89% N/A N/A 44% F
Market Capitalization 0.36B N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 20.94 N/A N/A N/A N/A
Price / Cash Flow Ratio -9.18 N/A N/A N/A N/A
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -129.91% N/A N/A N/A N/A
Return on Invested Capital -65.68% N/A N/A N/A N/A
Return on Assets -34.66% N/A N/A N/A N/A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 7.74 N/A N/A N/A N/A
Short Percent 2.57% N/A N/A N/A N/A
Beta 1.49 N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.